aptamer d3

**Aptamer d3** is a therapeutic DNA aptamer comprising a 50 nucleotide sequence, identified via cell-SELEX against the doxorubicin-resistant human hepatocellular carcinoma cell line (HepG2/DOX). It demonstrates high affinity and specificity for multidrug-resistant hepatocellular carcinoma cells. Mechanistically, aptamer d3 binds to and inhibits multidrug resistance protein 1 (MDR1), a membrane efflux transporter associated with drug resistance in cancer cells. Binding of aptamer d3 blocks MDR1, increases intracellular accumulation of chemotherapeutic agents such as doxorubicin, vincristine, and paclitaxel, and thereby reverses multidrug resistance, improving cytotoxicity against cancer cells both in vitro and in vivo. It is being investigated as both a monotherapy and a chemotherapy adjuvant for the treatment of multidrug-resistant liver cancer[1][2].

Other names

aptamer d3